C4 therapeutics to present preliminary monotherapy data from the ongoing phase 1 trial of cft1946 as a mini oral presentation at the esmo congress 2024

Watertown, mass., july 16, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing phase 1/2 clinical trial of cft1946, a novel bidac™ degrader in mutant braf v600 solid tumors, will be presented as a mini oral presentation at the european society for medical oncology (esmo) congress 2024 taking place september 13 – 17, 2024 in barcelona, spain.
CCCC Ratings Summary
CCCC Quant Ranking